Ming‐Shen Dai

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 609 citations · Full text

Medicine, Oncology, Pharmacology +15

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2019 · 100 citations

Medicine, Oncology, Pharmacology +16

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Cancer-Specific Transgene Expression Mediated by Systemic Injection of Nanoparticles

Edward J. Chisholm, Georges Vassaux, Pilar Martín‐Duque et al. · Cancer Research · 2009 · 75 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +17

Antroquinonol differentially modulates T cell activity and reduces interleukin‐18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis

Pei‐Yi Tsai, Shuk‐Man Ka, Jia‐Ming Chang et al. · Arthritis & Rheumatism · 2011 · 59 citations

Medicine, Immunology, Pharmacology +17